IRON insider disposes 90K shares; holdings drop to 500,621
Rhea-AI Filing Summary
Director Kevin Bitterman reported a series of open-market sales of Disc Medicine, Inc. common stock executed on 10/07/2025 and 10/08/2025. The filings show 90,000 shares sold across multiple transactions at weighted average prices ranging roughly from $68.00 to $72.62, reducing his reported indirect beneficial holdings to 500,621 shares held through affiliated Atlas Venture funds. The sales are disclosed under Section 16 and were signed by an attorney-in-fact on 10/09/2025. The report identifies the holdings as indirect via Atlas Venture entities and includes footnotes describing the fund ownership structure and weighted-average price ranges for each tranche sold.
Positive
- None.
Negative
- Director-associated funds sold 90,000 shares on 10/07/2025–10/08/2025
- Weighted-average sale prices ranged approximately from $68.00 to $72.62, indicating exits across multiple price points
- Reported beneficial ownership fell to 500,621 shares following the transactions, reducing the reported fund stake
Insights
Insider sold material stake via fund vehicles; filing shows compliance.
These transactions show a director-associated manager selling 90,000 shares across two days, with holdings recorded as indirect via Atlas Venture funds. The structure and footnotes clarify the sales were by the funds and the reporting person disclaims direct beneficial ownership except for any pecuniary interest.
The key dependency is that the holdings are indirect through venture funds, which often trade for fund-level liquidity rather than personal reasons. Monitor subsequent Section 16 filings for follow-up sales or purchases within 30 days if applicable.
Sales executed at prices ~$68–$72.62 reduce reported stake to 500,621 shares.
The reported weighted-average price ranges indicate the sales were executed in multiple tranches, likely over several market trades. The price range and volume—90,000 shares—are large enough to be noticed by market participants depending on the stock's daily volume.
Watch for any pattern of continued disposals or fund-level liquidity events in the coming weeks, which could affect short-term supply-demand dynamics for the stock.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 8,219 | $68.26 | $561K |
| Sale | Common Stock | 12,386 | $69.31 | $858K |
| Sale | Common Stock | 25,400 | $70.54 | $1.79M |
| Sale | Common Stock | 12,689 | $71.51 | $907K |
| Sale | Common Stock | 13,267 | $72.39 | $960K |
| Sale | Common Stock | 11,378 | $68.01 | $774K |
| Sale | Common Stock | 6,661 | $69.01 | $460K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.00 to $68.12 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (3), (4), (5), (6), (7) and (8). These shares are held by Atlas Venture Opportunity Fund I, LP ("Opportunity I"). The general partner of Opportunity I is Atlas Venture Associates Opportunity I, LP ("Associates I"). Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. The Reporting Person is a member of Associates I LLC and disclaims beneficial ownership of such securities held by Opportunity I, except to the extent of his pecuniary interest therein, if any. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.00 to $69.08 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.01 to $69.00 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.0173 to $69.9882 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.0293 to $71.028 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.03 to $72.0233 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.0474 to $72.6152 inclusive. These shares are held by Atlas Venture Opportunity Fund II, LP ("Opportunity II"). The general partner of Opportunity II is Atlas Venture Associates Opportunity II, LP ("Associates II"). Atlas Venture Associates Opportunity II, LLC ("Associates II LLC") is the general partner of Associates II. The Reporting Person is a member of Associates II LLC and disclaims beneficial ownership of such securities held by Opportunity II, except to the extent of his pecuniary interest therein, if any. These shares are held by Atlas Venture Fund XII, L.P. ("Atlas XII"). The general partner of Atlas XII is Atlas Venture Associates XII, L.P. ("Associates XII"). Atlas Venture Associates XII, LLC ("Associates XII LLC") is the general partner of Associates XII. The Reporting Person is a member of Associates XII LLC and disclaims beneficial ownership of such securities held by Atlas XII, except to the extent of his pecuniary interest therein, if any.
